A UK pharmaceutical company, Crescent Pharma Limited, has announced its third product recall in three months related to blood pressure medication. This recall involves 2.5mg ramipril capsules, prompted by a packaging mistake that may lead to serious health risks.
Crescent Pharma Issues Third Recall of Ramipril Medication
The recall covers a specific batch of the 2.5mg ramipril blood pressure medication due to concerns that some cartons might contain higher 10mg doses. This action is classified as a precautionary class 2 recall, initiated by Crescent Pharma after healthcare professionals discovered 10mg blister strips in sealed cartons of the 2.5mg product.
Details of the Recall
- Affected Lot Number: GR155023
- Expiration Date: 08/2027
- Pack Size: 28 capsules
- First Distributed: 16 January 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that the error originated in the packaging process, as both product batches were manufactured at the same site. This recall follows earlier recalls for the 10mg and 5mg ramipril capsules, which occurred on 20 April and 6 March respectively, all attributed to similar packaging errors.
Risks Associated with Incorrect Dosage
The primary risk linked to the recalled 2.5mg capsules is the unintentional overdosing of patients. Those receiving the incorrect 10mg dosage could experience significant health issues, including lightheadedness, fatigue, or altered kidney function. This is especially dangerous for vulnerable patient groups.
Dr. Alison Cave, the chief safety officer at the MHRA, emphasized the importance of healthcare professionals’ assessments for patients who may have ingested the higher dose. “Signs and symptoms should be closely monitored,” she advised.
Guidance for Healthcare Providers
Healthcare professionals are instructed to:
- Immediately stop supplying the impacted batch of ramipril 2.5mg capsules.
- Quarantine any remaining stock.
- Return the affected products to their supplier using approved processes.
Pharmacists must contact patients who received the impacted products, advising them to check their medications. If records are incomplete, they should identify all patients who were dispensed this batch from 16 January 2026 to 22 May 2026. Those with defective packs should return them and consult their GP for potential treatment adjustments.
Industry Response
The National Pharmacy Association (NPA) has voiced concerns about the financial burden of these recalls on pharmacies. NPA Chair Olivier Picard stated that manufacturers should face penalties for the errors they cause. He highlighted the strain on pharmacists during these recalls, emphasizing the disruption to patient trust in their medication.
As the healthcare community responds to this ongoing issue, patients are urged to report any adverse reactions and consult medical professionals for any concerns regarding their medication.
